Publications database

Approximately 40% of women stop endocrine therapy for hormone-receptor-positive breast cancer within the first 5 years of prescribed treatment because of side effects. Musculoskeletal complaints are among the most frequently reported side effects. [...]

Influenza viruses continue to pose a global health threat, and available antiviral therapies are limited by resistance and reduced efficacy. Host-directed drugs such as MEK inhibitors have emerged as promising alternatives. [...]

Natural killer (NK) cells are cytotoxic innate lymphoid cells which directly kill tumor cells, thus represent an attractive target for immunotherapy. However, NK cells face immunosuppression in the tumor microenvironment (TME), rendering them dysfunctional. [...]

Checkpoint inhibitors targeting PD-1 have shown unprecedented efficacy in some cancer patients; however, co-expression of the immune-checkpoint LAG-3 by tumor infiltrating lymphocytes (TILs) might hinder such efficacy. PD-1 and LAG-3 are established markers of T-cell exhaustion in cancer and are co-expressed by stem-like CD8 T cells, a population critical for the response to anti-PD1 therapy, providing the rationale for their dual-blockade. [...]

The association of prostate-specific antigen (PSA) persistence after radical prostatectomy (RP) with inferior prognosis was demonstrated in a systematic review. However, all patients in the included studies lacked a prostate-specific membrane antigen Positron-Emissions-Tomography (PSMA-PET) before salvage radiotherapy (SRT). [...]

Breast fibrosis (BF) after radiotherapy remains one of the most dreaded late toxicities in breast cancer care, yet multiple additive predictors struggle to capture its underlying biological complexity. Radiation-induced lymphocyte apoptosis (RILA) has recently been associated with the risk of fibrosis more than 10 years post-RT. [...]

The incidence of oropharyngeal cancer (OPC) driven by human papillomavirus (HPV) is increasing in high-income countries. Recurrent tumors remain a major cause of HPV-OPC mortality, yet reliable biomarkers for post-treatment monitoring are lacking. [...]

Ameloblastomas are locally aggressive jaw tumors, primarily treated with radical surgery, which often results in significant functional and aesthetic morbidity. Innovative, personalized treatment strategies to reduce patient burden without compromising oncologic control remain lacking. [...]

Colorectal cancer (CRC) survival is improving, yet long-term survivors remain at risk for cancer- and treatment-related late effects, which may emerge many years after diagnosis and treatment. We aimed to summarize evidence on late effects and their risk factors reported ≥5 years after CRC diagnosis, compared to cancer-free controls.The literature search for this scoping review was conducted in PubMed, EMBASE and Web of Science from inception to November 18, 2025. [...]